Unknown

Dataset Information

0

The GALNT14 Genotype Predicts Postoperative Outcome of Pancreatic Ductal Adenocarcinoma.


ABSTRACT: Pancreatic ductal adenocarcinoma (PDA) is notorious for its poor prognosis. The current mainstay of treatment for PDA is surgical resection followed by adjuvant chemotherapy. However, it is difficult to predict the post-operative outcome because of the lack of reliable markers. The single-nucleotide polymorphism (SNP) of N-acetylgalactosaminyltransferase14 (GALNT14) has been proven to predict the progression-free survival (PFS), overall survival (OS) and response to chemotherapy in various types of gastrointestinal (GI) cancers. However, its role in PDA has not been studied. This study aims to investigate whether the GALNT14 SNP genotype can be a prognostic marker for PDA. A cohort of one hundred and three PDA patients having received surgical resection were retrospectively enrolled. GALNT14 genotypes and the clinicopathological parameters were correlated with postoperative prognosis. The genotype analysis revealed that 19.4%, 60.2% and 20.4% of patients had the GALNT14 "TT", "TG" and "GG" genotypes, respectively. The patients with the "GG" genotype had a mean OS time of 37.1 months (95% confidence interval [CI]: 18.2-56.1) and those with the "non-GG" genotype had a mean OS time of 16.1 months (95% CI: 13.1-19.2). Kaplan-Meier analysis showed that the "GG" genotype had a significantly better OS compared to the "non-GG" genotype (p = 0.005). However, there was no significant difference between the "GG" and "non-GG" genotypes in PFS (p = 0.172). The baseline characteristics between patients with the "GG" and "non-GG" genotypes were compared, and no significant difference was found. Univariate followed by multivariate Cox proportional hazard models demonstrated the GALNT14 "GG" genotype, negative resection margin, and locoregional disease as independent predictors for favorable OS (p = 0.003, p = 0.037, p = 0.021, respectively). Sensitivity analysis was performed in each subgroup to examine the relationship of GALNT14 with different clinicopathological variables and no heterogeneity was found. The GALNT14 "GG" genotype is associated with favorable survival outcome, especially OS, in patients with resected PDA and could serve as a prognostic marker.

SUBMITTER: Chiang CC 

PROVIDER: S-EPMC6947583 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

The <i>GALNT14</i> Genotype Predicts Postoperative Outcome of Pancreatic Ductal Adenocarcinoma.

Chiang Chun-Cheng CC   Yeh Chau-Ting CT   Hwang Tsann-Long TL   Chu Yu-De YD   Lim Siew-Na SN   Chen Chun-Wei CW   Kuo Chia-Jung CJ   Le Puo-Hsien PH   Chen Tsung-Hsing TH   Lin Wey-Ran WR  

Journal of clinical medicine 20191216 12


Pancreatic ductal adenocarcinoma (PDA) is notorious for its poor prognosis. The current mainstay of treatment for PDA is surgical resection followed by adjuvant chemotherapy. However, it is difficult to predict the post-operative outcome because of the lack of reliable markers. The single-nucleotide polymorphism (SNP) of <i>N-acetylgalactosaminyltransferase14</i> (<i>GALNT14</i>) has been proven to predict the progression-free survival (PFS), overall survival (OS) and response to chemotherapy in  ...[more]

Similar Datasets

| S-EPMC4998711 | biostudies-literature
| S-EPMC5593633 | biostudies-literature
| S-EPMC4293116 | biostudies-literature
| S-EPMC9500295 | biostudies-literature
| S-EPMC3282755 | biostudies-literature
| S-EPMC4650682 | biostudies-other
| S-EPMC9406071 | biostudies-literature
| S-EPMC5996282 | biostudies-literature
| S-EPMC5719052 | biostudies-literature
| S-EPMC6692205 | biostudies-literature